

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON THE ADJUSTMENT TO REMAKRS ON SCOPE OF REINBURSEMENT FOR CERTAIN DRUGS OF THE COMPANY UNDER THE NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 13 December 2023, the National Healthcare Security Administration (国家医疗保障局) (the “NHS”) and the Ministry of Human Resources and Social Security (人力资源和社会保障部) issued the Notice on the Issuance of the Reimbursement Drug List for National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2023) (国家基本医疗保险、工伤保险和生育保险药品目录) (2023年) (the “2023 National Reimbursement Drug List”). Under the 2023 National Reimbursement Drug List, the remarks on scope of reimbursement for certain drugs of the Company are adjusted (the “Adjustment”). The details of the Adjustment are as set out below.

1. The Adjustment

Drug name	Before the Adjustment			After the Adjustment (2023 National Reimbursement Drug List)		
	Drug No.	National medical insurance category	Remarks (scope of reimbursement)	Drug No.	National medical insurance category	Remarks (scope of reimbursement)
Mai Luo Tong (脉络通)	475	Category B	Limited to: Peripheral vascular thrombotic diseases (周围血管血栓性病变)	478	Category B	/
Zi Long Jin Pian (紫龙金片)	931	Category B	Limited to: Lung cancer (肺癌)	941	Category B	/
Yi Fei Qing Hua Gao (益肺清化膏)	947	Category B	Limited to: Advanced-stage lung cancer (晚期肺癌)	958	Category B	Limited to: Tumor patients (肿瘤患者)

An Gong Niu Huang Wan (安宫牛黄丸)	296	Category A	Limited to: Emergency first aid and rescue in cases of coma caused by febrile convulsions or stroke (高热惊厥或中风所致的昏迷急救、抢救时使用)	298	Category A	Limited to: Clearing heat and detoxification, calming convulsions, and opening orifices. Used for febrile diseases, pericardial pathogens, febrile convulsions, coma and delirium, and for those with stroke-induced coma, encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, and sepsis presenting the above symptoms (清热解毒，镇惊开窍。用于热病，邪入心包，高热惊厥，神昏谵语；中风昏迷及脑炎、脑膜炎、中毒性脑病、脑出血、败血症见上述证候者)
---	-----	------------	---	-----	------------	---

2. Impact on the Company

The Adjustment as stated above is expected to have a positive impact on the future promotion and application of relevant drugs of the Company. The Adjustment would benefit more patients, and at the same time, it is also expected to drive the sales growth of the Company's products and usher in new growth opportunities for the Company.

3. Risk warning

The 2023 National Reimbursement Drug List will come into effect on 1 January 2024, and the specific implementation requirements shall be subject to further document(s)/ information released by relevant government departments including the NHSA.

Shareholders of the Company and potential investors should note that the sales of drugs are uncertain as they may be affected by various factors, are advised to make investments in a rational manner and be aware of the risks involved.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
15 December 2023